Q

Quoin Pharmaceuticals Ltd
NASDAQ:QNRX

Watchlist Manager
Quoin Pharmaceuticals Ltd
NASDAQ:QNRX
Watchlist
Price: 0.585 USD -5.65% Market Closed
Market Cap: 3m USD
Have any thoughts about
Quoin Pharmaceuticals Ltd?
Write Note

Intrinsic Value

QNRX doesn't have a meaningful market cap.
QNRX's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one QNRX stock under the Base Case scenario is 2.695 USD. Compared to the current market price of 0.585 USD, Quoin Pharmaceuticals Ltd is Undervalued by 78%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

QNRX Intrinsic Value
2.695 USD
Undervaluation 78%
Intrinsic Value
Price
Q
Worst Case
Base Case
Best Case

Valuation Backtest
Quoin Pharmaceuticals Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for QNRX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about QNRX?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Quoin Pharmaceuticals Ltd

Provide an overview of the primary business activities
of Quoin Pharmaceuticals Ltd.

What unique competitive advantages
does Quoin Pharmaceuticals Ltd hold over its rivals?

What risks and challenges
does Quoin Pharmaceuticals Ltd face in the near future?

Has there been any significant insider trading activity
in Quoin Pharmaceuticals Ltd recently?

Summarize the latest earnings call
of Quoin Pharmaceuticals Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Quoin Pharmaceuticals Ltd.

Provide P/S
for Quoin Pharmaceuticals Ltd.

Provide P/E
for Quoin Pharmaceuticals Ltd.

Provide P/OCF
for Quoin Pharmaceuticals Ltd.

Provide P/FCFE
for Quoin Pharmaceuticals Ltd.

Provide P/B
for Quoin Pharmaceuticals Ltd.

Provide EV/S
for Quoin Pharmaceuticals Ltd.

Provide EV/GP
for Quoin Pharmaceuticals Ltd.

Provide EV/EBITDA
for Quoin Pharmaceuticals Ltd.

Provide EV/EBIT
for Quoin Pharmaceuticals Ltd.

Provide EV/OCF
for Quoin Pharmaceuticals Ltd.

Provide EV/FCFF
for Quoin Pharmaceuticals Ltd.

Provide EV/IC
for Quoin Pharmaceuticals Ltd.

Show me price targets
for Quoin Pharmaceuticals Ltd made by professional analysts.

What are the Revenue projections
for Quoin Pharmaceuticals Ltd?

How accurate were the past Revenue estimates
for Quoin Pharmaceuticals Ltd?

What are the Net Income projections
for Quoin Pharmaceuticals Ltd?

How accurate were the past Net Income estimates
for Quoin Pharmaceuticals Ltd?

What are the EPS projections
for Quoin Pharmaceuticals Ltd?

How accurate were the past EPS estimates
for Quoin Pharmaceuticals Ltd?

What are the EBIT projections
for Quoin Pharmaceuticals Ltd?

How accurate were the past EBIT estimates
for Quoin Pharmaceuticals Ltd?

Compare the revenue forecasts
for Quoin Pharmaceuticals Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Quoin Pharmaceuticals Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Quoin Pharmaceuticals Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Quoin Pharmaceuticals Ltd compared to its peers.

Compare the P/E ratios
of Quoin Pharmaceuticals Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Quoin Pharmaceuticals Ltd with its peers.

Analyze the financial leverage
of Quoin Pharmaceuticals Ltd compared to its main competitors.

Show all profitability ratios
for Quoin Pharmaceuticals Ltd.

Provide ROE
for Quoin Pharmaceuticals Ltd.

Provide ROA
for Quoin Pharmaceuticals Ltd.

Provide ROIC
for Quoin Pharmaceuticals Ltd.

Provide ROCE
for Quoin Pharmaceuticals Ltd.

Provide Gross Margin
for Quoin Pharmaceuticals Ltd.

Provide Operating Margin
for Quoin Pharmaceuticals Ltd.

Provide Net Margin
for Quoin Pharmaceuticals Ltd.

Provide FCF Margin
for Quoin Pharmaceuticals Ltd.

Show all solvency ratios
for Quoin Pharmaceuticals Ltd.

Provide D/E Ratio
for Quoin Pharmaceuticals Ltd.

Provide D/A Ratio
for Quoin Pharmaceuticals Ltd.

Provide Interest Coverage Ratio
for Quoin Pharmaceuticals Ltd.

Provide Altman Z-Score Ratio
for Quoin Pharmaceuticals Ltd.

Provide Quick Ratio
for Quoin Pharmaceuticals Ltd.

Provide Current Ratio
for Quoin Pharmaceuticals Ltd.

Provide Cash Ratio
for Quoin Pharmaceuticals Ltd.

What is the historical Revenue growth
over the last 5 years for Quoin Pharmaceuticals Ltd?

What is the historical Net Income growth
over the last 5 years for Quoin Pharmaceuticals Ltd?

What is the current Free Cash Flow
of Quoin Pharmaceuticals Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Quoin Pharmaceuticals Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Quoin Pharmaceuticals Ltd

Current Assets 13.2m
Cash & Short-Term Investments 12.6m
Other Current Assets 650.7k
Non-Current Assets 833.3k
Intangibles 533.3k
Other Non-Current Assets 300k
Current Liabilities 4m
Accounts Payable 819.7k
Accrued Liabilities 2.5m
Short-Term Debt 600k
Non-Current Liabilities 2.6m
Long-Term Debt 2.6m
Efficiency

Earnings Waterfall
Quoin Pharmaceuticals Ltd

Revenue
0 USD
Operating Expenses
-8.9m USD
Operating Income
-8.9m USD
Other Expenses
661.9k USD
Net Income
-8.3m USD

Free Cash Flow Analysis
Quoin Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

The company has commenced 2024 on a strong note, optimistic about building on the positive initial data for its lead asset targeting Netherton syndrome, a rare genetic disorder. With the age eligibility for clinical studies now lowered to 14, the company expects a diverse study population and plans to enroll as many eligible pediatric patients as possible. Despite the challenges, the balance sheet remains robust after a successful capital raise and a strategic equity line of credit (ELOC) arrangement, placing the company in a robust position to complete clinical testing. Top-line results from the blinded study are anticipated early in 2025, with further data from the open-label study expected to be released throughout the year.

What is Earnings Call?
Fundamental Scores

QNRX Profitability Score
Profitability Due Diligence

Quoin Pharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

Quoin Pharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

QNRX Solvency Score
Solvency Due Diligence

Quoin Pharmaceuticals Ltd's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Low D/E
Long-Term Solvency
58/100
Solvency
Score

Quoin Pharmaceuticals Ltd's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

QNRX Price Targets Summary
Quoin Pharmaceuticals Ltd

Wall Street analysts forecast QNRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for QNRX is 4.76 USD with a low forecast of 2.02 USD and a high forecast of 10.5 USD.

Lowest
Price Target
2.02 USD
245% Upside
Average
Price Target
4.76 USD
714% Upside
Highest
Price Target
10.5 USD
1 695% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for QNRX?

Click here to dive deeper.

Dividends

Quoin Pharmaceuticals Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for QNRX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

QNRX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Quoin Pharmaceuticals Ltd

Country

Israel

Industry

Life Sciences Tools & Services

Market Cap

3m USD

Dividend Yield

0%

Description

Quoin Pharmaceuticals Ltd. is a specialty pharmaceutical company engaged in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Contact

Kfar Saba
23 Ha'Taas St.
+97299741444.0
quoinpharma.com

IPO

1989-11-01

Employees

-

Officers

Co-Founder, CEO & Chairman
Dr. Michael Myers Ph.D.
Co-Founder, COO & Director
Ms. Denise Carter
Chief Financial Officer
Mr. Gordon Bruce Dunn J.D.

See Also

Discover More
What is the Intrinsic Value of one QNRX stock?

The intrinsic value of one QNRX stock under the Base Case scenario is 2.695 USD.

Is QNRX stock undervalued or overvalued?

Compared to the current market price of 0.585 USD, Quoin Pharmaceuticals Ltd is Undervalued by 78%.

Back to Top